Progress update: Fluid and imaging biomarkers in Alzheimer's disease

Biological Psychiatry

Volumn 75, Issue 7, 2014, Pages 520-526

  Sutphen, Courtney L ^a   Fagan, Anne M ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; diagnosis; neuroimaging; prognosis

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; SOLANEZUMAB; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER'S DISEASE; BIOMARKER; CEREBROSPINAL FLUID; DIAGNOSIS; NEUROIMAGING; PROGNOSIS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84896387447     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.07.031     Document Type: Review

References (100)

1. World Health Organization and Alzheimer's Disease International Dementia: A Public Health Priority 2012 World Health Organization Geneva
2. J.L. Price, A.I. Ko, M.J. Wade, S.K. Tsou, D.W. McKeel, and J.C. Morris Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease Arch Neurol 58 2001 1395 1402
3. T. Montine, C. Phelps, T. Beach, E. Bigio, N. Cairns, and D. Dickson et al. National Institute on Aging-Alzheimer's guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach ACTA Neuropathol 123 2012 1 11
4. R. Handels, P. Aalten, C. Wolfs, M. OldeRikkert, P. Scheltens, and P. Visser et al. Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: The research protocol of a prospective cohort study BMC Neurol 12 2012 72
5. R.J. Perrin, R. Craig-Schapiro, J.P. Malone, A.R. Shah, P. Gilmore, and A.E. Davis et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease PLoS One 6 2011 e16032
6. CR Jack Jr, M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
7. Eli Lilly and Company (2012): Lilly announces detailed results of the Phase III solanezumab EXPEDITION studies following a presentation of the independent analyses by the Alzheimer's disease cooperative study (ADCS) [press release]. Available at: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID= 711933. Accessed August 12, 2013.
8. Pfizer Inc (2012): Pfizer announces co-primary clinical endpoints not met in second phase III bapineuzumab study in mild-to-moderate Alzheimer's disease patients who do not carry the Apoe4 genotype [press release]. Available at: http://www.businesswire.com/news/home/20120806006130/en/Pfizer-Announces-Co- Primary-Clinical-Endpoints-Met-Phase. Accessed August 12, 2013.
9. Eli Lilly and Company (2012): Lilly provides update on next steps for solanezumab [press release]. Available at: http://newsroom.lilly.com/ releasedetail.cfm?releaseid=726309. Accessed August 12, 2013.
10. K. Blennow, A. Wallin, and O. Häger Low frequency of post-lumbar puncture headache in demented patients Acta Neurol Scand 88 1993 221 223
11. E. Peskind, A. Nordberg, T. Darreh-Shori, and H. Soininen Safety of lumbar puncture procedures in patients with Alzheimer's disease Curr Alzheimer Res 6 2009 290 292
12. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
13. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656
14. A.M. Fagan, M.A. Mintun, R.H. Mach, S.-Y. Lee, C.S. Dence, and A.R. Shah et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans Ann Neurol 59 2006 512 519
15. T. Grimmer, M. Riemenschneider, H. Förstl, G. Henriksen, W.E. Klunk, and C.A. Mathis et al. Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biol Psychiatry 65 2009 927 934
16. W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, and E.M. Reiman et al. Relationships between biomarkers in aging and dementia Neurology 73 2009 1193 1199
17. T. Tapiola, I. Alafuzoff, S.-K. Herukka, L. Parkkinen, P. Hartikainen, and H. Soininen et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 2009 382 389
18. A. Forsberg, O. Almkvist, H. Engler, A. Wall, B. Langstrom, and A. Nordberg High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters Curr Alzheimer Res 7 2010 55 66
19. S. Hong, O. Quintero-Monzon, B.L. Ostaszewski, D.R. Podlisny, W.T. Cavanaugh, and T. Yang et al. Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation J Neurosci 31 2011 15861 15869
20. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349
21. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
22. B.J. Snider, A.M. Fagan, C. Roe, A.R. Shah, E.A. Grant, and C. Xiong et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type Arch Neurol 66 2009 638 645
23. M.D. Naylor, J.H. Karlawish, S.E. Arnold, A.S. Khachaturian, Z.S. Khachaturian, and V.M.Y. Lee et al. Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit Alzheimers Dement 8 2012 445 452
24. R. Sperling, and K. Johnson Biomarkers of Alzheimer disease: Current and future applications to diagnostic criteria Continuum (Minneap Minn) 19 2013 325 338
25. C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, and E. Vanmechelen et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neurosci Lett 297 2001 187 190
26. S. Schraen-Maschke, N. Sergeant, C-M. Dhaenens, S. Bombois, V. Deramecourt, and M-L Caillet-Boudin et al. Tau as a biomarker of neurodegenerative diseases Biomark Med 2 2008 363 384
27. K. Buerger, M. Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff, and S.J. Teipel et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 2006 3035 3041
28. K. Yamada, J. Cirrito, F. Stewart, H. Jiang, M. Finn, and B. Holmes et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice J Neurosci 31 2011 13110 13117
29. N. Kfoury, B.B. Holmes, H. Jiang, D.M. Holtzman, and M.I. Diamond Trans-cellular propagation of tau aggregation by fibrillar species J Biol Chem 287 2012 19440 19451
30. E. Blom, V. Giedraitis, H. Zetterberg, H. Fukumoto, K. Blennow, and B. Hyman et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the Apoe ε4/ε4 genotype Dement Geriatr Cogn 27 2009 458 464
31. K. Buerger, S. Teipel, R. Zinkowski, K. Blennow, H. Arai, and R. Engel et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects Neurology 63 2004 1144
32. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395 e6
33. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, and S. Chalbot et al. CSF biomarker variability in the Alzheimer's Association quality control program Alzheimers Dement 9 2013 251 261
34. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe, and S.G. Younkin Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease J Neurosci 21 2001 372 381
35. R.J. Bateman, C. Xiong, T.L.S. Benzinger, A.M. Fagan, A. Goate, and N.C. Fox et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
36. J.-M. Lee, K. Blennow, N. Andreasen, O. Laterza, V. Modur, and J. Olander et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients Clin Chem 54 2008 1617 1623
37. R. Tarawneh, G. D'Angelo, E. Macy, C. Xiong, D. Carter, and N.J. Cairns et al. Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease Ann Neurol 70 2011 274 285
38. R. Tarawneh, J.-M. Lee, J.H. Ladenson, J.C. Morris, and D.M. Holtzman CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease Neurology 78 2012 709 719
39. C. Østergaard, J.S. Johansen, T. Benfield, P.A. Price, and J.D. Lundgren YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis Clin Vaccine Immunol 9 2002 598 604
40. R. Craig-Schapiro, R.J. Perrin, C.M. Roe, C. Xiong, D. Carter, and N.J. Cairns et al. YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease Biol Psychiatry 68 2010 903 912
41. N. Mattsson, S. Tabatabaei, P. Johansson, O. Hansson, U. Andreasson, and J.-E. Månsson et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: Elevated chitotriosidase activity but lack of diagnostic utility Neuromol Med 13 2011 151 159
42. A.M. Fagan, and R.J. Perrin Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease Biomark Med 6 2012 455 476
43. D. Galasko, and T.J. Montine Biomarkers of oxidative damage and inflammation in Alzheimer's disease Biomark Med 4 2010 27 36
44. M.I. Kester, P.G. Scheffer, M.J. Koel-Simmelink, H. Twaalfhoven, N.A. Verwey, and R. Veerhuis et al. Serial CSF sampling in Alzheimer's disease: Specific versus non-specific markers Neurobiol Aging 33 2012 1591 1598
45. X. Han, A.M. Fagan, H. Cheng, J.C. Morris, C. Xiong, and D.M. Holtzman Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia Ann Neurol 54 2003 115 119
46. R. Mayeux, and N. Schupf Blood-based biomarkers for Alzheimer's disease: Plasma Aβ40 and Aβ42, and genetic variants Neurobiol Aging 32 suppl 1 2011 S10 S19
47. A.M. Fagan, M.A. Mintun, A.R. Shah, P. Aldea, C.M. Roe, and R.H. Mach et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease EMBO Mol Med 1 2009 371 380
48. M. Ingelson, M. Blomberg, E. Benedikz, L.O. Wahlund, E. Karlsson, and E Vanmechelen et al. Tau immunoreactivity detected in human plasma, but no obvious increase in dementia Dement Geriatr Cogn 10 1999 442 445
49. H. Zetterberg, D. Wilson, U. Andreasson, L. Minthon, K. Blennow, and J. Randall et al. Plasma tau levels in Alzheimer's disease Alzheimers Res Ther 5 2013 9
50. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, and M. Edwards et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI PLoS One 6 2011 e28092
51. M.M. Reddy, R. Wilson, J. Wilson, S. Connell, A. Gocke, and L. Hynan et al. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening Cell 144 2011 132 142
52. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception Alzheimers Dement 8 2012 S1 S68
53. N. Fox, E. Warrington, P. Freeborough, P. Hartikainen, A. Kennedy, and J. Stevens et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study Brain 119 1996 2001 2007
54. M. Bobinski, M. de Leon, A. Convit, S. De Santi, J. Wegiel, and C. Tarshish et al. MRI of entorhinal cortex in mild Alzheimer's disease Lancet 353 1999 38 40
55. C.R. Jack, R.C. Petersen, Y.C. Xu, P.C. O'Brien, G.E. Smith, and R.J. Ivnik et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment Neurology 52 1999 1397
56. R. Clifford, J. Jack, R.C. Petersen, Y.C. Xu, S.C. Waring, P.C. O'Brien, and E.G. Tangalos et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease Neurology 49 1997 786 794
57. J. Csernansky, L. Wang, S. Joshi, J. Miller, M. Gado, and D Kido et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type Neurology 55 2000 1636 1643
58. N.C. Fox, R.I. Scahill, W.R. Crum, and M.N. Rossor Correlation between rates of brain atrophy and cognitive decline in AD Neurology 52 1999 1687
59. P. Vemuri, H.J. Wiste, S.D. Weigand, L.M. Shaw, J.Q. Trojanowski, and M.W. Weiner et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change Neurology 73 2009 294 301
60. M.E. Raichle, A.M. MacLeod, A.Z. Snyder, W.J. Powers, D.A. Gusnard, and G.L. Shulman A default mode of brain function PNAS 98 2001 676 682
61. B.C. Dickerson, D.H. Salat, D.N. Greve, E.F. Chua, E. Rand-Giovannetti, and D.M. Rentz et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD Neurology 65 2005 404 411
62. L. Wang, Y. Zang, Y. He, M. Liang, X. Zhang, and L. Tian et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: Evidence from resting state fMRI Neuroimage 31 2006 496 504
63. F. Agosta, M. Pievani, C. Geroldi, M. Copetti, G.B. Frisoni, and M. Filippi Resting state fMRI in Alzheimer's disease: Beyond the default mode network Neurobiol Aging 33 2012 1564 1578
64. M.D. Greicius, G. Srivastava, A.L. Reiss, and V. Menon Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI PNAS 101 2004 4637 4642
65. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
66. M.R. Brier, J.B. Thomas, A.Z. Snyder, T.L. Benzinger, D. Zhang, and M.E. Raichle et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression J Neurosci 32 2012 8890 8899
67. D.S. Karow, L.K. McEvoy, C. Fennema-Notestine, D.J. Hagler, R.G. Jennings, and J.B. Brewer et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease Radiology 256 2010 932 942
68. Y. Chen, D.A. Wolk, J.S. Reddin, M. Korczykowski, P.M. Martinez, and E.S. Musiek et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease Neurology 77 2011 1977 1985
69. C.R. Jack Jr, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
70. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 2004 306 319
71. C.A. Mathis, N.S. Mason, B.J. Lopresti, and W.E. Klunk Development of positron emission tomography β-amyloid plaque imaging agents Semin Nucl Med 42 2012 423 432
72. W.E. Klunk, and C.A. Mathis The future of amyloid-beta imaging: A tale of radionuclides and tracer proliferation Curr Opin Neurol 21 2008 683 687
73. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun et al. Use of florbetapir-PET for imaging β-amyloid pathology JAMA 305 2011 275 283
74. C.R. Jack, V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease Brain 132 2009 1355 1365
75. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, M. Storandt, and A.M. Goate et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease Arch Neurol 66 2009 1469 1475
76. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K Någren et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study Neurology 73 2009 754 760
77. F. Zeng, and M.M. Goodman Fluorine-18 radiolabeled heterocycles as PET tracers for imaging β-amyloid plaques in Alzheimer's disease Curr Top Med Chem 13 2013 909 919
78. J. Luo, and C. Xiong Youden index and associated cutoff points for three ordinal diagnostic groups Commun Stat Simulat 42 2012 1213 1234
79. C. Xiong, D.W. McKeel, J.P. Miller, and J.C. Morris Combining correlated diagnostic tests: Application to neuropathologic diagnosis of Alzheimer's disease Med Decis Making 24 2004 659 669
80. M.S. Pepe, and M.L. Thompson Combining diagnostic test results to increase accuracy Biostatistics 1 2000 123 140
81. D. Cox Regression models and life-tables J Roy Stat Soc B Met 34 1972 187 220
82. D. Commenges Inference for multi-state models from interval-censored data Stat Methods Med Res 11 2002 167 182
83. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study Lancet Neurol 5 2006 228 234
84. G. Li, I. Sokal, J.F. Quinn, J.B. Leverenz, M. Brodey, and G.D. Schellenberg et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study Neurology 69 2007 631 639
85. A.M. Fagan, L.M. Shaw, C. Xiong, H. Vanderstichele, M.A. Mintun, and J.Q. Trojanowski et al. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology Arch Neurol 68 2011 1137 1144
86. S. Hall, A. Öhrfelt, R. Constantinescu, U. Andreasson, Y. Surova, and F. Bostrom et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders Arch Neurol 69 2012 1445 1452
87. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, and K. Blennow et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359
88. M. Björkqvist, M. Ohlsson, L. Minthon, and O. Hansson Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease PLoS One 7 2012 e29868
89. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, and S.E. Arnold et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
90. H.D. Soares, W.Z. Potter, E. Pickering, M. Kuhn, F.W. Immermann, and D.M. Shera et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease Arch Neurol 69 2012 1310 1317
91. E. Westman, J.S. Muehlboeck, and A. Simmons Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion Neuroimage 62 2012 229 238
92. R. Bateman, P. Aisen, B. De Strooper, N. Fox, C. Lemere, and J. Ringman et al. Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease Alzheimers Res Ther 3 2011 1
93. E.M. Reiman, J.B.S. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, and N. Ayutyanont et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments J Alzheimers Dis 26 2011 321 329
94. R.A. Sperling, C.R. Jack, and P.S. Aisen Testing the right target and right drug at the right stage Sci Trans Med 3 2011 111cm33
95. M. Andersson, H. Zetterberg, L. Minthon, K. Blennow, and E. Londos The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia Int J Geriatr Psychiatry 26 2011 100 105
96. T. Reis, C.O. Brandão, E.S. Freire Coutinho, E. Engelhardt, and J. Laks Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: Preliminary findings from Brazil CNS Neurosci Ther 18 2012 524 529
97. K. Buerger, R. Zinkowski, S.J. Teipel, H. Arai, J. DeBernardis, and D. Kerkman et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231 Am J Psychiat 160 2003 376 379
98. N.S.M. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, and P.M. van de Ven et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 78 2012 47 54
99. B. Van Everbroeck, A.J.E. Green, P. Pals, J.J. Martin, and P. Cras Decreased levels of amyloid-β 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients J Alzheimers Dis 1 1999 419 424
100. M. Otto, J. Wiltfang, H. Tumani, I. Zerr, L. Maria, and J. Kornhuber et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurosci Lett 225 1997 210 212